A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Brief summary (registry, in English)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.

What you commit to

• Study type: Interventional · Phase 3
• Participants enrolled: 20284
• From 11 Apr 2023 to the primary completion date, 8 Dec 2026
• 1,006 sites in 39 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1006)

Sites in registry order. Save your city in your profile to sort them by distance.